Goldman Sachs Resumes Express Scripts (ESRX) at Conviction Buy

April 3, 2012 7:07 AM EDT
Get Alerts ESRX Hot Sheet
Price: $72.67 -0.67%

Rating Summary:
    11 Buy, 17 Hold, 2 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 13 | Down: 22 | New: 54
Trade ESRX Now!
Join SI Premium – FREE
Goldman Sachs resumes coverage on Express Scripts (NASDAQ: ESRX) with a Conviction Buy rating and $70 price target, suggesting 26% following approval of the Medco merger.

The firm notes that with the merger Express Scripts becomes a top 10 US HC company (market cap) growing EPS over 20% on average through 2015.

Goldman said catalysts included: 22% three-year EPS CAGR, a robust 2013 selling season, as generics and mail benefit slows Express' unmatched scale and specialty capabilities will drive earnings.

For an analyst ratings summary and ratings history on Express Scripts click here. For more ratings news on Express Scripts click here.

Shares of Express Scripts closed at $55.50 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

New Coverage

Related Entities

Goldman Sachs, Earnings

Add Your Comment